What are the side effects of pegylated asparaginase?

Side Effects of PEG-Asparaginase

PEG-asparaginase causes several serious toxicities that are more frequent and severe in adults than children, including coagulopathy, thrombosis, hyperglycemia, pancreatitis, and liver toxicity, requiring specific monitoring schedules and management protocols. 1

Major Toxicities

Hypersensitivity Reactions

• Clinical allergic reactions range from transient flushing/rash and drug fever (Grade 1) to life-threatening anaphylaxis with bronchospasm, hypotension, and loss of consciousness (Grades 3-4) 1
• Severe allergic reactions are rare with PEG-asparaginase compared to native asparaginase in adults 1
• Anaphylaxis presents with breathing difficulty, dizziness, hypotension, cyanosis, and may lead to death 1
• Silent inactivation occurs when neutralizing antibodies render the drug ineffective without overt allergy symptoms, requiring therapeutic drug monitoring 1

Hepatotoxicity

• Liver toxicity is of greater concern in adults than children 1
• Risk increases with body mass index >30 kg/m² and presence of hepatosteatosis on ultrasound 1
• Hypertriglyceridemia can be severe and prolonged, potentially requiring continuous intravenous insulin and heparin infusion 2
• Triglyceride elevations correlate with overall toxicity burden 3

Coagulopathy and Thrombosis

• Coagulopathy and thromboembolism are significant complications requiring careful monitoring 1
• PEG-asparaginase lowers antithrombin levels, though antithrombin supplementation has not been shown to reduce venous thromboembolism incidence 4
• Venous thromboembolism occurs in approximately 11-17% of adult patients receiving PEG-asparaginase 4

Pancreatitis

• Pancreatitis risk increases with higher numbers of PEG-asparaginase doses 5
• In one study, 15 doses versus 8 doses showed increased pancreatitis (RR 0.31 for 8 doses, meaning 8 doses reduced risk) 5
• Six doses versus two doses increased pancreatitis risk significantly (RR 4.84) 5

Metabolic Complications

• Hyperglycemia is a recognized complication requiring monitoring 1
• Hyperammonemia occurs with high incidence (88% of patients showing levels >100 μmol/L) 3
• Symptoms range from mild anorexia and nausea to headache, vomiting, dizziness, and lethargy 3
• Severe hyperammonemia may require early treatment interruption 3

Other Toxicities

• Osteonecrosis can occur, though risk varies with dosing regimens 5
• Severe infections increase with prolonged dexamethasone administration during asparaginase therapy 1
• Myelotoxicity and mucositis worsen with early high-dose anthracyclines given concurrently 1

Critical Management Considerations

Monitoring Requirements

• Establish specific schedules for toxicity monitoring before initiating therapy 1
• Therapeutic drug monitoring should be performed in all patients to detect silent inactivation 1
• Measure serum asparaginase activity within 7 days of first dose and after any gap ≥4 weeks 1
• Silent inactivation defined as day 7 level <0.1 IU/mL and/or day 14 level below lower limit of quantification 1

Dose Adjustments

• Adapt PEG-asparaginase schedule and dosing to age, BMI, and hepatosteatosis status 1
• Higher toxicity occurs with BMI >30 kg/m² and positive ultrasound for hepatosteatosis 1
• Avoid hepatotoxic drugs during expected asparaginase activity duration (14-30 days depending on dose) unless strictly clinically indicated 1

Switching Preparations

• Switch to Erwinia asparaginase if clinical allergy or silent inactivation occurs with PEG-asparaginase 1
• Do not switch from PEG-asparaginase to native E. coli asparaginase 1
• Subsequent allergy to Erwinia occurs in 3-33% of patients who had E. coli-derived preparation allergy 1